Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Ospemifene inhibited growth of dimethylbenzanthracene-induced mammary tumors
March 2nd, 2006
Ospemifene was shown to inhibit the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. "Ospemifene is a new selective estrogen receptor modulator (SERM) that is being developed for the treatment of urogenital atrophy and osteoporosis. Similarly to other SERMs, ospemifene exhibits antiestrogenic effects in breast tissue, which led to the hypothesis that it may be a potential breast cancer chemopreventive agent," researchers in the United States reported. "We first assessed the ability of ospemifene, compared to tamoxifen and raloxifene, to prevent dimethylbenzanthracene (DMBA)-induced mammary tumors in female Sencar mice....
Source: Women's Health Weekly (2006-03-02)
|
